clascoterone
Commercial- Indications
- Acne
Company intelligence / Profile preview
Cassiopea S.p.A.
Lainate, Milan, Italyold.cassiopea.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Commercial
01
Overview
Cassiopea has developed Winlevi (clascoterone), an FDA-approved topical treatment for acne. The company also has several other clinical candidates in development for dermatological conditions.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Small molecule drugsTopical treatmentsAntiandrogensAntibioticsIntegrin activators
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sun Pharma
Beyond the preview
Go deeper on Cassiopea S.p.A..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cassiopea S.p.A..